Show simple item record

dc.contributor.authorLipworth, W
dc.contributor.authorKerridge, I
dc.contributor.authorDay, R
dc.date.accessioned2014-07-28T23:12:47Z
dc.date.available2014-07-28T23:12:47Z
dc.date.issued2012
dc.identifier.citationTime for the Pharmaceutical Benefits Advisory Committee to set its own agenda Wendy L Lipworth, Ian Kerridge and Richard O Day Med J Aust 2012; 196 (6): 374-375.en_AU
dc.identifier.urihttp://hdl.handle.net/2123/11540
dc.description.abstractDrug subsidy recommendations should be informed by active assessment of current evidence and emerging treatments. Decisions about which medicines should be subsidised by the Australian Government on the Pharmaceutical Benefits Scheme (PBS) are based on recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) — an independent statutory body appointed by the government. The PBAC lists among its goals maximising the “value” that Australia derives from its health expenditure and “meet[ing] the health needs of the majority of the Australian community”. While the PBAC is generally thought to have in place good processes for working towards these goals, its decisions are increasingly contested by consumers, governments, clinicians and the pharmaceutical industryen_AU
dc.language.isoen_AUen_AU
dc.publisherAMPCo.en_AU
dc.titleTime for the Pharmaceutical Benefits Advisory Committee to set its own agendaen_AU
dc.typeArticleen_AU
dc.type.pubtypePublisher versionen_AU


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record